Blog

New hope for metastatic melanoma patients – Weill Cornell Medicine Meyer Cancer

Photo taken from Weill Cornell Medicine/X

Sep 22, 2024, 03:28

New hope for metastatic melanoma patients – Weill Cornell Medicine Meyer Cancer

Weill Cornell Medicine Meyer Cancer Center shared a post by Weill Cornell Medicine on X, adding the following:

“Check out the latest research from WCM Meyer Cancer Director Dr. Jedd Wolchok and colleagues, providing hope for patients with metastatic melanoma.”

Quoting Weill Cornell Medicine’s post:

“About half of patients with metastatic melanoma treated with a combo of immune checkpoint inhibitors survive cancer-free for 10 years or more, according to new trial findings led by WCM Meyer Cancer, Dana Farber, and Royal Marsden NHS.

Full story.”

Source: Weill Cornell Medicine Meyer Cancer Center/X and Weill Cornell Medicine/X

cancer cancer-free survival Dana-Farber Immune Checkpoint Inhibitors Jedd Wolchok metastatic melanoma Meyer Cancer Center OncoDaily Oncology Royal Marsden NHS Weill Cornell Medicine

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer

Black History Month 2025: Honoring Contributions to Oncology